Carisma Therapeutics is a biopharmaceutical company dedicated to developing a differentiated and proprietary cell therapy platform focused on engineered macrophages, cells that play a crucial role in both the innate and adaptive immune response. The first applications of the platform, developed in collaboration with the University of Pennsylvania, are autologous chimeric antigen receptor (CAR)-macrophages for the treatment of solid tumors.

Stock Information

Data Provided by Refinitiv. Minimum 15 minutes delayed.

News Releases

07 Mar '23
Shares of Carisma to commence trading on Nasdaq under new ticker symbol "CARM" on March 8, 2023 Resulting cash position of approximately $140 million provides runway through 2024; expected to enable multiple clinical readouts across Carisma programs PHILADELPHIA, March 7, 2023 /PRNewswire/ -- 

Recent Events

Corporate Presentation